| 1/22 | US=34-A / Câncer Gil RA, araújo BCAB. Biologia molecular na oncologia. In: Guimarães JRQ. Manual de oncologia. 3ªed. São Paulo: BBS Editora, 2008. p. 1993-2002. BASES MOLECULARES DA CARCINOGENESE; ERB RECEPTORES; ANGIOGENESE; PROTEASSOMA; TERAPEUTICAS ALVO-ESPECIFICAS; ANTICORPOS MONOCLONAIS; PEQUENAS MOLECULAS; VACINAS; INIBIDORES DA M-TOR |
| 2/22 | US=6 / Quimioterapia Airley R. The proteasome. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 237-43. ISBN 978-0-470-09254-5. |
| 3/22 | US=22 / Urologia Garcia JA, Varizi SJA, Ganapathi R. Proteasome-NFkB signaling pathway: relevance in RCC. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 305-20. ISBN 978-1-58829-737-2. SISTEMA UBIQUITINA-PROTEASSOMA; VIA DE PROTEASSOMA NA RCC; INIBICAO DO PROTEASSOMA |
| 4/22 | US=22 / Urologia Kawabe M, Herrem CJ, Finke JH, Storkus WJ. EphA2: a novel target in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 347-66. ISBN 978-1-58829-737-2. RTK; CD8+ T LINFOCITOS; QUINASE DE TIROSINA RECEPTORA; PROTEASSOMA; TERAPIA COMBINATORIA; COMPLEXO PRINCIPAL DE HISTOCOMPATIBILIDADE |
| 5/22 | US=8 / Laboratório Lecker SH, Saric T, Goldberg AL. Protein degradation in cells. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone, 2009. p. 34-41. ISBN 978-0-443-06715-0. DEGRADACAO DE PROTEINAS; PROTEOLISE LISOSSOMAL; CONJUGACAO DA UBIQUITINA; INIBIDORES DE PROTEASSOMA; TERAPIA DO CANCER; DEGRADACAO ASSOCIADA AO RETICULO ENDOPLASMATICO; PROTEOLISE EM MITOCONDRIA; QUEBRA DE PROTEINA MUSCULAR; CAQUEXIA |
| 6/22 | US=85 / Biol/Mol Plantivaux A, Szegezdi E, Samali A, Egan L. Is there a role for nuclear factor kB in tumor necrosis factor-related apoptosis-inducing ligand resistance?. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 38-49. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. CANCER; APOPTOSE; RESISTENCIA; INIBIDORES DE PROTEASSOMA; SUPER-REPRESSOR; MTOR; TRAIL; NF-KB |
| 7/22 | US=9 / Pediatria Smith MA. Evolving molecularly targeted therapies and biotherapeutics. In: Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2006. p. 366-404. ISBN 978-0-7817-5492-7. ONCOLOGIA PEDIATRICA; CANCER INFANTIL; CRIANCA; BIOTERAPIA; TERAPIA MOLECULAR; APOPTOSE; VIAS DE SINALIZACAO EXTRACELULAR; ENZIMAS HISTONA DESACETILASE; FARNESIL-TRANSFERASE; PROTEASSOMA; ANGIOGENESE |
| 8/22 | US=15 / Gastro El-Rayes B. An overview of clinical trials of targeted therapies in pancreatic cancer. In: Lowy AM, Leach SD, Philip PA. Pancreatic cancer. New York: Springer, 2008. p. 565-75. ISBN 978-0-387-69250-0. TERAPIAS-ALVO. CANCER DE PANCREAS; INIBIDORES DE PROTEASSOMA; INIBIDORES DA ANGIOGENESE; RAS INIBIDORES |
| 9/22 | US=35 / Biol/Mol Neckers L. Heat shock protein 90 and the proteasome: housekeeping proteins become novel molecular targets for cancer therapy. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 701-10. ISBN 978-1-4160-3703-3. PROTEINA DE CHOQUE TERMICO 90; PROTEASSOMA; ALVOS MOLECULARES; CANCER. TERAPIA; HSP90 |
| 10/22 | US=2 / Tórax Huynh M, Lara PN Jr. Proteasome inhibition in nonsmall cell lung cancer therapy. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 400-10. ISBN 978-1-4051-5112-2. INIBICAO DO PROTEASSOMA EM NAO PEQUENA; TERAPIA DE CANCER DE PULMAO DE CELULAS |
| 11/22 | US=39 / Câncer Motarjemi M, Hallett WHD, Li M, Murphy WJ. Proteasome inhibition: potential for sensitization of immune effector mechanisms in cancer. In: Bonavida B. Sensitization of cancer cells for chemo/immuno/radio-therapy. Los Angeles: Humana Press, 2008. p. 51-60. ISBN 978-1-58829-989-5. INIBICAO DO PROTEASSOMA; SENSIBILIZACAO DE MECANISMOS EFETORES IMUNES; CANCER; BORTEZOMIBE; CDDO |
| 12/22 | US=56 / Biol/Mol O'Brien MA, Moravec RA, Riss TL, Bulleit RF. Homogeneous, bioluminescent proteasome assays. In: Mor G, Alvero AB. Apoptosis and cancer: methods and protocols. New Jersey: Humana Press, 2008. p. 163-81. (Methods in Molecular Biology) ISBN 978-1-58829-457-9. 20 ANOS PROTEASSOMA; BIOLUMINESCENCIA; LUCIFERASE; AMINOLUCIFERIN; ENSAIO PROTEASE BIOLUMINESCENTE; 20 ANOS ENSAIO PROTEASSOMA |
| 13/22 | US=64 / Câncer Chauhan D, Singh A, Anderson K. Proteasome inhibitors as therapy in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 421-32. (Comtemporary Hematology) ISBN 978-1-934115-82-4. TERAPIA EM MIELOMA MULTIPLO. INIBIDORES DE PROTEASSOMA; HOMEOSTASE CELULAR NORMAL; AGENTES ANTICANCERIGENOS. INIBIDORES DE PROTEASSOMA |
| 14/22 | US=58 / Câncer Alao JP. G1 phase cyclins in cancer development and progression. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 123-53. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FASE G1; CICLINAS EM CANCER; CICLO CELULAR; FASE G1; CICLINA D1; CICLINA E; CANCER; ONCOGENE; UBIQUITINA; PROTEASSOMA 26S; TERAPIA DO CANCER |
| 15/22 | US=80 / Biol/Mol Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 161-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. LEUCEMIA MIELOIDE AGUDA; BIOMARCADORES; PHARMACOPROTEOMICS; ACIDO TRANS-RETINOICO; INIBIDORES DE QUINASE DE TIROSINA; HISTONA DEACETILASE INIBIDORES; INIBIDORES DE PROTEASSOMA |
| 16/22 | US=84 / Biol/Mol Gold LI, Lecanda J. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: mechanisms of cell cycle regulation by TGF-B disabled in cancer. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 213-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. P27KIP1; CKS1; SKP2; CANCRO ENDOMETRIAL; UBIQUITINA-PROTEASSOMA |
| 17/22 | US=84 / Biol/Mol Band A, Laiho M. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: transforming growth factor-B in cancer therapy. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 243-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. TGF-BETA; SMAD; TRANSDUCAO DE SINAL; SNON; PROTEASSOMA; UBIQUITINA; SUMO; DEGRADACAO |
| 18/22 | US=77-J / Câncer Gimenes DL, Costa AABA. Princípios de terapia sistêmica. In: Lopes A, Chammas R, Iyeyasu H. Oncologia para a graduação. 3ª ed. São Paulo: Lemar, 2013. p. 229-34. ISBN 8-5866523-7-0. CANCER. TERAPIA; TERAPIA SISTEMICA; QUIMIOTERAPIA; VIAS DE ADMINISTRACAO; QUIMIOTERAPIA. EFEITOS ADVERSOS; AGENTES ALQUILANTES; ANALOGOS DA PLATINA; ANTIMETABOLITOS; DNA TOPOIMERASES; ANTICORPOS MONOCLONAIS; INIBIDORES DE TIROSINAQUINASE; INIBIDORES DA MTOR; INIBIDORES DO PROTEASSOMA |
| 19/22 | US=36 / Patologia Schiffer D. The ubiquitin-proteasome system. In: ___. Brain tumor pathology: current diagnostic hotspots and pitfalls. The Netherlands: Springer, 2006. p. 183-7. ISBN 978-1-4020-3998-0. |
| 20/22 | US=8 / Quimioterapia O'Connor OA. Proteasome inhibitors. In: Chabner BA, Longo DL. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. p. 621-40. ISBN 978-0-7817-5628-6. INIBIDORES DE PROTEASSOMA; QUIMICA; MECANISMOS DE ACAO; FARMACOLOGIA |